Skip to content
Home
About Us
Why LinKinVax ?
Science
Leadership Team
Partnering & featured deal
Company Responsability
Research & development
Science
Our products
Linkinvax pipeline
Medias
News
Press releases
SUBSCRIBE TO UPDATE
Investors
A unique project
SUBSCRIBE TO UPDATE
Join us (fr)
Contact Us
Home
About Us
Why LinKinVax ?
Science
Leadership Team
Partnering & featured deal
Company Responsability
Research & development
Science
Our products
Linkinvax pipeline
Medias
News
Press releases
SUBSCRIBE TO UPDATE
Investors
A unique project
SUBSCRIBE TO UPDATE
Join us (fr)
Contact Us
Home
About Us
Why LinKinVax ?
Science
Leadership Team
Partnering & featured deal
Company Responsability
Research & development
Science
Our products
Linkinvax pipeline
Medias
News
Press releases
SUBSCRIBE TO UPDATE
Investors
A unique project
SUBSCRIBE TO UPDATE
Join us (fr)
Contact Us
Home
About Us
Why LinKinVax ?
Science
Leadership Team
Partnering & featured deal
Company Responsability
Research & development
Science
Our products
Linkinvax pipeline
Medias
News
Press releases
SUBSCRIBE TO UPDATE
Investors
A unique project
SUBSCRIBE TO UPDATE
Join us (fr)
Contact Us
LinKinVax completes first batch production of “pancov”,its next generation multi-variant vaccine against covid and other coronaviruses
20 July 2023
Télécharger le communiqué de presse